Tumor-associated antigens (TAAs) such as the Wilms tumor gene WT1 have the potential to generate tumor antigen-specific T cells which promote a GvL effect and display selective cytotoxicity to leukemic cells [2,3,4] while avoiding side effects of allogeneic HSCT like graft versus host disease (GvHD). This evidence concerns the gene WT1 and neoplasm.